CLAIMS

What is claimed is:

1. A composition for treating hidradenitis suppurtiva in a subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject in need thereof [(1S)-2,2-difluorocyclo-propyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone; or, a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein said salt is the *p*-toluenesulfonic acid salt.

3. The composition of claims 1 or 2, wherein the treatment reduces inflammatory nodules, abscess and draining fituals as measured by the subject's HiSCR score.

4. The composition of claims 1 or 2, wherein the treatment reduces the median size of the subject’s hidradenitis suppurativa lesions.

5. The composition of claims 1 or 2, wherein the treatment reduces the subject's pain associated with the subject's hidradenitis suppurativa lesions.

6. The composition of claims 1 or 2, wherein the treatment increases the subject's time to develop new hidradenitis suppurativa lesions.

7. A composition for treating hidradenitis suppurtiva in a human subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject in need thereof [(1S)-2,2-difluorocyclo-propyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone; or, a pharmaceutically acceptable salt thereof.

8. The composition of claim 7, wherein said effective amount is about 0.01 to about 100 mg/kg of body weight/day, in a single dose or as divided doses administered two, three or four times per day.